This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pupa, S. M. Articles by Tagliabue, E. Search for Related Content PubMed PubMed Citation Articles by Pupa, S. M. Articles by Tagliabue, E.

Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1

¹ Molecular Biology Unit, ² Laboratory of Proteomics, and ³ Human Tumor Immunobiology Unit, Department of Experimental Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy and ⁴ Department of Cell Biology, Medical University of South Carolina, Charleston, South Carolina

Requests for reprints: Sylvie Menard, Molecular Biology Unit, Department of Experimental Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, Milan, Italy. Phone: 39-02-2390-2571; Fax: 39-02-2390-3073; E-mail: sylvie.menard{at}istitutotumori.mi.it.

Doxorubicin treatment was found to augment the expression of the extracellular matrix (ECM) protein fibulin-1 in cultured human breast cancer cell lines and in MDA-MB-361 tumors grown in athymic mice. Doxorubicin was also found to augment tumor expression of the fibulin-1–binding proteins fibronectin and laminin-1. Growth of breast cancer cell lines on Matrigel, an ECM extract containing fibulin-1 and laminin-1, resulted in lower levels of doxorubicin-induced apoptosis as compared with controls. Moreover, tumors formed by injection of athymic mice with MDA-MB-361 cells mixed with Matrigel were significantly more doxorubicin resistant and displayed lower levels of apoptosis compared with those that formed in the absence of Matrigel. Monoclonal antibodies against fibulin-1 reversed Matrigel-dependent doxorubicin resistance. Furthermore, small interfering RNA–mediated suppression of fibulin-1 expression in breast cancer cells resulted in a 10-fold increase in doxorubicin sensitivity as compared with control cells. Together, these findings point to a role for fibulin-1 in breast cancer chemoresistance. [Cancer Res 2007;67(9):4271–7]

This article has been cited by other articles:

				H. Seeliger, P. Camaj, I. Ischenko, A. Kleespies, E. N. De Toni, S. E. Thieme, H. Blum, G. Assmann, K.-W. Jauch, and C. J. Bruns EFEMP1 Expression Promotes In vivo Tumor Growth in Human Pancreatic Adenocarcinoma Mol. Cancer Res., February 1, 2009; 7(2): 189 - 198. [Abstract] [Full Text] [PDF]

				A.-M. Tokes, A. M. Szasz, A. Farkas, A. I. Toth, M. Dank, L. Harsanyi, B. A. Molnar, I. A. Molnar, Z. Laszlo, Z. Rusz, et al. Stromal Matrix Protein Expression Following Preoperative Systemic Therapy in Breast Cancer Clin. Cancer Res., January 15, 2009; 15(2): 731 - 739. [Abstract] [Full Text] [PDF]